《肿瘤靶向药物控释》.pptVIP

药物控释 肿瘤靶向 Tumor-Targeting Drug Controlled Release 小组成员： 厉从雷 张成彬 王文楷 杨迁 王锐 content 1. Preface 2. Tumor microenvironment 3. Drug targeting 4. Pitfalls in drug targeting to tumors 5. The impact factors of the drug release 6. Reference 正常组织 癌变部位 Drug Load 装载 定位 Targeting Drug Release 释放 Many different systems have been evaluated for drug targeting to tumors over the years. Routinely used systems include liposomes, polymers, micelles, nanoparticles and antibodies. 胶束 Micelles 树枝状聚合物 Dendrimers Liposomes 微脂囊 聚合物-药物 偶联物 Polymer-drug conjugates Drug Load 装载 Conventional chemotherapeutic agents are distributed non-speci?cally in the body affecting both normal and tumor cells. Given the potency of modern pharmacological agents, tissue selectivity is a major issue. The ultimate goal of cancer therapeutics is to increase the survival time and the quality of life of the patient by reducing the systemic toxicity of chemotherapy The idea of exploiting vascular abnormalities of tumors, avoid in penetration into normal tissue interstitium while allowing access to tumors, becomes particularly attractive. In this context, the tumor targeting of nanomedicine-based therapeutics has emerged as one approach to overcome the lack of speci?city of conventional chemotherapeutic agents . The speci?c tumor targeting of Nano carriers leads to better pro?les of pharmacokinetics and pharmacodynamics, controlled and sustained release of drugs, an improved speci?city, an increased internalization and intracellular delivery and, more importantly, a lower systemic toxicity. The tumor targeting consists in “passive targeting” and “active targeting”; however, the active targeting process cannot be separated from the passive because it occurs only after passive accumulation in tumors . New Molecular targeted anticancer agents currently used in clinical trials illustrate the success of the targeting concept. The representati